Drugs approved since legislation to speed up the approval process at the US Food and Drug Administration are more likely to have received black box warnings or been withdrawn from the market, according to a new analysis appearing in Health Affairs.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: caution urged in use of gene drives, and more.
NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.
PLOS Biology has asked researchers how they envision the future of genetics and genomics.
Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."